PMID- 24940450
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 7
IP  - 5
DP  - 2014 May
TI  - Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a 
      retrospective pooled analysis of randomized controlled trials.
PG  - 1420-1426
AB  - A standard systemic therapy for patients with human epidermal growth factor 
      receptor 2 (HER2)-negative advanced breast cancer (ABC) is yet to be identified. 
      Sorafenib has been developed for the treatment of solid tumors, including breast 
      cancer, as an oral multikinase inhibitor with antiangiogenic and 
      antiproliferative activity. The aim of the present study was to assess the 
      efficacy and safety of sorafenib in patients with HER2-negative ABC by performing 
      a meta-analysis. A literature search was applied to databases, including PubMed, 
      EMBASE, the Cochrane Library Databases, American Society of Clinical Oncology and 
      the European Society for Medical Oncology, with the search terms 'advanced breast 
      cancer' and 'sorafenib' and relevant studies were selected for analysis. The data 
      extracted from the selected studies included progression-free survival (PFS), 
      time to progression (TTP), overall survival (OS) and overall response rate (ORR). 
      Major adverse events (AEs) were also analyzed. A total of four randomized 
      controlled trials containing 844 cases were identified. Combined results revealed 
      that when compared with chemotherapy (or with anti-hormone receptor therapy) 
      alone, sorafenib-based therapy significantly increased the PFS [hazard ratio 
      (HR), 0.78; 95% confidence interval (CI), 0.54-1.02] and TTP (HR, 0.74; 95% CI, 
      0.50-0.97), but not the OS (HR, 0.95; 95% CI, 0.75-1.15) and ORR (relative risk, 
      1.19; 95% CI, 1.01-1.39). In addition, the incidence of grade 3/4 AEs, including 
      hand-foot skin syndrome, anemia, fatigue, rash and stomatitis, were significantly 
      increased in patients that received sorafenib-based therapy. Therefore, the 
      results from the current meta-analysis indicated that sorafenib-based therapy 
      improved the PFS and TTP in patients with HER2-negative ABC, but not the OS and 
      ORR. In addition, combination treatment was associated with increased toxicities 
      and frequently required dose reductions.
FAU - Tan, Qi-Xing
AU  - Tan QX
AD  - Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, 
      Guangxi 530021, P.R. China.
FAU - Qin, Qing-Hong
AU  - Qin QH
AD  - Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, 
      Guangxi 530021, P.R. China.
FAU - Lian, Bin
AU  - Lian B
AD  - Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, 
      Guangxi 530021, P.R. China.
FAU - Yang, Wei-Ping
AU  - Yang WP
AD  - Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, 
      Guangxi 530021, P.R. China.
FAU - Wei, Chang-Yuan
AU  - Wei CY
AD  - Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, 
      Guangxi 530021, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20140305
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3991527
OTO - NOTNLM
OT  - advanced breast cancer
OT  - meta-analysis
OT  - sorafenib
EDAT- 2014/06/19 06:00
MHDA- 2014/06/19 06:01
PMCR- 2014/03/05
CRDT- 2014/06/19 06:00
PHST- 2013/11/01 00:00 [received]
PHST- 2014/02/24 00:00 [accepted]
PHST- 2014/06/19 06:00 [entrez]
PHST- 2014/06/19 06:00 [pubmed]
PHST- 2014/06/19 06:01 [medline]
PHST- 2014/03/05 00:00 [pmc-release]
AID - etm-07-05-1420 [pii]
AID - 10.3892/etm.2014.1603 [doi]
PST - ppublish
SO  - Exp Ther Med. 2014 May;7(5):1420-1426. doi: 10.3892/etm.2014.1603. Epub 2014 Mar 
      5.